HWH International Inc.
HWH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HWH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HWH
HWH International Inc. (HWH) is a company with minimal revenue and a going concern warning, reporting cash of $1.5M as of June 30, 2026 [sec].
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 78 clinical trials · 3 catalysts for HWH International Inc..
HWH International Inc. (HWH) is a company with minimal revenue and a going concern warning, reporting cash of $1.5M as of June 30, 2026 [sec].
- Cash and equivalents of $1.5M as of June 30, 2026 [sec].
- Total revenue of $0.1M and net income of $0.2M for the period ending June 30, 2026 [sec].
- Shareholders' equity of $2.6M and no total debt as of June 30, 2026 [sec].
- The company has received a Nasdaq deficiency letter but it does not immediately affect trading [sec · filed 2026-05-29].
- Management has expressed substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-07-30].
What works
- The company has no debt, with total debt reported as $0.0M as of June 30, 2026 [sec].
- Management believes available cash, anticipated cash from operations, and related-party financing are sufficient to fund operations for at least the next 12 months [sec_mda · as of 2026-07-30].
What to weigh
- The company reported a net loss, loss from operations, and negative cash flow from operating cafés in the six months ended June 30, 2026, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-07-30].
- Total assets decreased from $4.6M at December 31, 2025 to $4.5M at June 30, 2026, while liabilities decreased but remain significant relative to cash [sec_mda · as of 2026-07-30].
- The company received a Nasdaq deficiency letter, indicating potential non-compliance with listing requirements [sec · filed 2026-05-29].
From the filings
Quoted directly from source documents.
Cash and equivalents as of June 30, 2026
“1,506,036 as of June 30, 2026”
SEC MD&A · July 30, 2026
Going concern warning
“These factors raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · July 30, 2026
Nasdaq deficiency letter received
“The Letter has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market”
SEC filings · May 29, 2026
Catalyst timeline
- 2027-07-15 · Phase3_Topline — Phase 3 Topline: An Open Label, Randomized Non-Inferiority Trial Comparing Safety and Immunogenicity of Intradermal V
- 2027-08-30 · Phase3_Topline — Phase 3 Topline: A Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunog
- 2030-01-01 · Phase3_Topline — Phase 3 Topline: Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donor
Risks & what to watch (3)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern due to net loss, operating losses, and negative cash flow [sec_mda · as of 2026-07-30].
- Nasdaq listing deficiency — Received a deficiency letter from Nasdaq, though no immediate effect on trading [sec · filed 2026-05-29].
- Low cash runway — Cash of $1.5M as of June 30, 2026, with ongoing losses and minimal revenue of $0.1M [sec].
What to watch
- Ability to maintain Nasdaq listing and resolve any deficiency [sec · filed 2026-05-29].
- Cash burn rate and whether the company can secure additional financing or achieve profitability [sec_mda · as of 2026-07-30].
- Any updates on the company's business strategy or cafe operations, which have been a source of losses [sec_mda · as of 2026-07-30].
Sources: Competitor trials · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run HWH International Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HWH International Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.65 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
3 upcoming, next in ~319d
1 buy · 1 sell (180d)
Catalysts
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 1.2%
- Days to cover
- 0.1
- Shares short
- 16,524
- Daily short volume (Jun 8, 2026)
- 68.4%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HWH short interestGovernance
Frequently asked questions
What is the AI investment thesis for HWH International Inc.?
HWH International Inc. (HWH) is a company with minimal revenue and a going concern warning, reporting cash of $1.5M as of June 30, 2026 [sec].
What is HWH International Inc.'s next catalyst?
HWH International Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open Label, Randomized Non-Inferiority Trial Comparing Safety and Immunogenicity of Intradermal V" — expected July 15, 2027.
Who is the CEO of HWH International Inc.?
Mr. Heng Fai Chan is the chief executive officer of HWH International Inc. (HWH).
Where is HWH International Inc. headquartered?
HWH International Inc. (HWH) is headquartered in Bethesda, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.